SCHEMBL4743847

SCHEMBL4743847

CC1(C)Oc2ccc3ccc(=O)oc3c2[C@@H](O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 1.00
▸ TDP1 Q9NUW8 1/20 0.67
▸ KDM4E B2RXH2 13/20 0.64
▸ ALDH1A1 P00352 11/20 0.64
▸ HPGD P15428 10/20 0.64
▸ GAA P10253 4/20 0.64
▸ MAPT P10636 3/20 0.64
▸ MEN1 O00255 3/20 0.64
▸ KMT2A Q03164 3/20 0.64
▸ TSHR P16473 2/20 0.64
▸ RCE1 Q9Y256 1/20 0.63
▸ CYP3A4 P08684 4/20 0.60
▸ HSD17B10 Q99714 4/20 0.60
▸ HTT P42858 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ ABCB1 P08183 1/20 0.54
▸ TP53 P04637 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29624043 1.00 L3MBTL1 (1.00) L3MBTL1TDP1KDM4EALDH1A1HPGD
SCHEMBL19419823 0.87 L3MBTL1 (0.77) L3MBTL1TDP1KDM4EALDH1A1HPGD
SCHEMBL13799158 0.79 L3MBTL1 (0.66) L3MBTL1TDP1KDM4EALDH1A1HPGD
SCHEMBL14523893 0.78 KDM4E (1.00) L3MBTL1TDP1KDM4EALDH1A1HPGD
SCHEMBL31237484 0.77 KDM4E (0.78) L3MBTL1TDP1KDM4EALDH1A1HPGD
SCHEMBL30565430 0.76 TDP1 (0.64) L3MBTL1TDP1KDM4EALDH1A1HPGD
(+)-Lomatin SCHEMBL29707947 0.75 KDM4E (1.00) L3MBTL1TDP1KDM4EALDH1A1HPGD
Lomatin SCHEMBL6273711 0.75 KDM4E (1.00) L3MBTL1TDP1KDM4EALDH1A1HPGD
SCHEMBL4742405 0.72 KDM4E (0.82) L3MBTL1TDP1KDM4EALDH1A1HPGD
SCHEMBL31598298 0.72 KDM4E (0.82) L3MBTL1TDP1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109912556-B Benzopyrone skeleton derivative and preparation method and application thereof 复旦大学 2022-11-08 — — CN disclosed
CN-109111419-B 7, 8-coumarin derivative containing substituent, preparation method and application thereof 复旦大学 2022-07-08 — — CN disclosed
CN-112358457-B Method for synthesizing chiral endocyclic lactone 武汉大学 2022-07-05 — — CN disclosed
WO-2008100977-A2 CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS N.V. ORGANON (NL) 2008-08-21 — — WO disclosed
CN-1636997-A Substituted tricyclocoumarin compound and its prepn and anti-HIV application INST OF TOXICANT PHARMACOLOGY (CN) 2005-07-13 — — CN disclosed
US-20040162337-A1 Lactone-type acidic compounds CITY UNIVERSITY OF HONG KONG (HK) 2004-08-19 — — US disclosed
EP-0810861-B1 SUKSDORFIN ANALOGS, COMPOSITIONS THEREOF, AND METHODS FOR MAKING AND USING THEREOF UNIV NORTH CAROLINA (US) 2002-06-05 — — EP disclosed
US-6319929-B1 VIRAL DISEASES AND HIV TREATMENT THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2001-11-20 — — US disclosed
US-5847165-A Suksdorfin analogs, compositions thereof, and methods for making and using thereof THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1998-12-08 — — US disclosed
EP-0810861-A4 SUKSDORFIN ANALOGS, COMPOSITIONS THEREOF, AND METHODS FOR MAKING AND USING THEREOF UNIV NORTH CAROLINA (US) 1998-07-08 — — EP disclosed
US-5726204-A RETROVIRUS INHIBITORS BIOTECH RESEARCH LABORATORIES (US) 1998-03-10 — — US disclosed
EP-0810861-A1 SUKSDORFIN ANALOGS, COMPOSITIONS THEREOF, AND METHODS FOR MAKING AND USING THEREOF The University of North Carolina at Chapel Hill (US) 1997-12-10 — — EP disclosed
US-5637589-A VIRICIDES; THERAPY FOR RETROVIRUS OR AIDS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1997-06-10 — — US disclosed
WO-1996025930-A1 SUKSDORFIN ANALOGS, COMPOSITIONS THEREOF, AND METHODS FOR MAKING AND USING THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1996-08-29 — — WO disclosed
WO-1995029920-A1 KHELLACTONE DERIVATIVES AND RELATED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AND IMMUNOSTIMULATING AGENTS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1995-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162337-A1 Lactone-type acidic compounds ACSL1, ELOVL1, FASN L3MBTL1 1435/4885TDP1 4639/4885KDM4E 4576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback